Clinical Trials Logo

Clinical Trial Summary

This study evaluates positron emission tomography for the diagnosis of immune checkpoint inhibitor-related myocarditis. Immune checkpoint inhibitors have shown promising results in various malignancies however, several immune related adverse events have been described of which myocarditis carries the highest reported mortality. Diagnostic procedures, such as positron emission tomography, help find and diagnose myocarditis and provide functional or disease activity information as opposed to the largely structural/anatomic information.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To prospectively evaluate the sensitivity, specificity, positive predictive value, and negative predictive value of fludeoxyglucose F-18 (18 fluorodeoxyglucose) positive emission tomography computed tomography (PET CT) for the diagnosis of immune checkpoint inhibitor (ICI) related myocarditis. SECONDARY OBJECTIVES: I. To explore the clinical presentation and disease course of ICI-related myocarditis which include presenting symptoms (chest pain, dyspnea, fatigue), time from ICI initiation to symptom onset, hospitalization duration, time to peak troponin levels, and peak troponin levels. II. To evaluate biomarkers, including peak troponin, peak no probnp, admission troponin level, and admission nt probnp level, and imaging modalities of ICI-related myocarditis which include sensitivity, specificity, positive predictive value, and negative predictive value of cardiac magnetic resonance imaging (MRI). III. To determine the response to various treatments of ICI-related myocarditis which include time to resolution of symptoms, hospitalization duration, and peak troponin value stratified by treatment. IV. To observe the long-term outcomes, including late decline in left ventricular ejection fraction (LVEF) to < 50%, and survival after ICI related myocarditis, and monitoring of ICI-related myocarditis. V. To assess differences in PET CT imaging results between patients on steroid therapy versus not on steroid therapy for myocarditis. OUTLINE: Patients receive a low carbohydrate and high fat diet for 48-72 hours. Patients receive 18 fluorodeoxyglucose (FDG) then undergo PET CT. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05062395
Study type Observational
Source M.D. Anderson Cancer Center
Contact
Status Completed
Phase
Start date March 30, 2021
Completion date April 4, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05150704 - MYTHS - MYocarditis THerapy With Steroids Phase 3
Recruiting NCT04264455 - Evaluation of Long-term Incidence of Ventricular Arrhythmias in Patients With Acute Myocarditis
Recruiting NCT05335928 - Abatacept in Immune Checkpoint Inhibitor Myocarditis Phase 3
Recruiting NCT06323811 - Comparison of Free-breathing 3D Quantitative Perfusion in Patients With MINOCA and MINOCA-mimics N/A
Completed NCT05124223 - Analysis of Cardiac Damage Post Infection With SARS-CoV-2 and Post Vaccination Against COVID-19
Recruiting NCT03525639 - CMR Evaluation of Myocardial Inflammation Persistence After Acute Myocarditis: Prognostic Relevance N/A
Recruiting NCT06103123 - MYocarditis and/or Pericarditis Following mRNA COVID-19 VACCination National Surveillance Study
Not yet recruiting NCT03842592 - Ventricular Arrhythmia After Myocarditis in Sportsman N/A
Completed NCT05933902 - Multicenter Retrospective Observational Study of Acute Myocarditis in Korea